BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 25429521)

  • 1. Incidence of myocardial infarction and vascular death in elderly patients with atrial fibrillation taking anticoagulants: relation to atherosclerotic risk factors.
    Pastori D; Pignatelli P; Angelico F; Farcomeni A; Del Ben M; Vicario T; Bucci T; Raparelli V; Cangemi R; Tanzilli G; Lip GYH; Violi F
    Chest; 2015 Jun; 147(6):1644-1650. PubMed ID: 25429521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Family History of Atrial Fibrillation and Risk of Cardiovascular Events: A Multicenter Prospective Cohort Study.
    Pastori D; Menichelli D; Lip GYH; Sciacqua A; Violi F; Pignatelli P;
    Circ Arrhythm Electrophysiol; 2020 Sep; 13(9):e008477. PubMed ID: 32718257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inadequate anticoagulation by Vitamin K Antagonists is associated with Major Adverse Cardiovascular Events in patients with atrial fibrillation.
    Pastori D; Pignatelli P; Saliola M; Carnevale R; Vicario T; Del Ben M; Cangemi R; Barillà F; Lip GY; Violi F
    Int J Cardiol; 2015 Dec; 201():513-6. PubMed ID: 26318513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary 11-dehydro-thromboxane B2 is associated with cardiovascular events and mortality in patients with atrial fibrillation.
    Pastori D; Pignatelli P; Farcomeni A; Cangemi R; Hiatt WR; Bartimoccia S; Nocella C; Vicario T; Bucci T; Carnevale R; Lip GY; Violi F
    Am Heart J; 2015 Sep; 170(3):490-7.e1. PubMed ID: 26385032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated Care Management of Patients With Atrial Fibrillation and Risk of Cardiovascular Events: The ABC (Atrial fibrillation Better Care) Pathway in the ATHERO-AF Study Cohort.
    Pastori D; Pignatelli P; Menichelli D; Violi F; Lip GYH
    Mayo Clin Proc; 2019 Jul; 94(7):1261-1267. PubMed ID: 30551910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation.
    Gallego P; Roldán V; Torregrosa JM; Gálvez J; Valdés M; Vicente V; Marín F; Lip GY
    Circ Arrhythm Electrophysiol; 2012 Apr; 5(2):312-8. PubMed ID: 22319005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular risk stratification in patients with non-valvular atrial fibrillation: the 2MACE score.
    Pastori D; Farcomeni A; Poli D; Antonucci E; Angelico F; Del Ben M; Cangemi R; Tanzilli G; Lip GY; Pignatelli P; Violi F
    Intern Emerg Med; 2016 Mar; 11(2):199-204. PubMed ID: 26471883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flow-mediated dilation is associated with cardiovascular events in non-valvular atrial fibrillation patients.
    Perri L; Pastori D; Pignatelli P; Violi F; Loffredo L
    Int J Cardiol; 2015 Jan; 179():139-43. PubMed ID: 25464433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation.
    Carrero JJ; Evans M; Szummer K; Spaak J; Lindhagen L; Edfors R; Stenvinkel P; Jacobson SH; Jernberg T
    JAMA; 2014 Mar; 311(9):919-28. PubMed ID: 24595776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitral annular calcification predicts cardiovascular morbidity and mortality in middle-aged patients with atrial fibrillation: the Belgrade Atrial Fibrillation Study.
    Potpara TS; Vasiljevic ZM; Vujisic-Tesic BD; Marinkovic JM; Polovina MM; Stepanovic JM; Stankovic GR; Ostojic MC; Lip GYH
    Chest; 2011 Oct; 140(4):902-910. PubMed ID: 21436252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-alcoholic fatty liver disease (NAFLD), metabolic syndrome and cardiovascular events in atrial fibrillation. A prospective multicenter cohort study.
    Pastori D; Sciacqua A; Marcucci R; Del Ben M; Baratta F; Violi F; Pignatelli P;
    Intern Emerg Med; 2021 Nov; 16(8):2063-2068. PubMed ID: 33713286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention.
    Lamberts M; Gislason GH; Olesen JB; Kristensen SL; Schjerning Olsen AM; Mikkelsen A; Christensen CB; Lip GY; Køber L; Torp-Pedersen C; Hansen ML
    J Am Coll Cardiol; 2013 Sep; 62(11):981-9. PubMed ID: 23747760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and Risk Factors for Residual Adverse Events Despite Anticoagulation in Atrial Fibrillation: Results From Phase II/III of the GLORIA-AF Registry.
    Ding WY; Lane DA; Gupta D; Huisman MV; Lip GYH;
    J Am Heart Assoc; 2022 Aug; 11(15):e026410. PubMed ID: 35876418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognosis of atrial fibrillation in patients with symptomatic peripheral arterial disease: data from the REduction of Atherothrombosis for Continued Health (REACH) Registry.
    Winkel TA; Hoeks SE; Schouten O; Zeymer U; Limbourg T; Baumgartner I; Bhatt DL; Steg PG; Goto S; Röther J; Cacoub PP; Verhagen HJ; Bax JJ; Poldermans D
    Eur J Vasc Endovasc Surg; 2010 Jul; 40(1):9-16. PubMed ID: 20385507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temporal trends of time in therapeutic range and incidence of cardiovascular events in patients with non-valvular atrial fibrillation.
    Pastori D; Farcomeni A; Saliola M; Del Sole F; Pignatelli P; Violi F; Lip GYH;
    Eur J Intern Med; 2018 Aug; 54():34-39. PubMed ID: 29655807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Causes of death and influencing factors of atrial fibrillation patients undergoing anticoagulation therapy].
    Hua C; Jiang C; He L; Jia ZX; Lyu WH; Tang RB; Sang CH; Long DY; Dong JZ; Ma CS; Du X
    Zhonghua Xin Xue Guan Bing Za Zhi; 2021 Apr; 49(4):353-359. PubMed ID: 33874685
    [No Abstract]   [Full Text] [Related]  

  • 17. Relationship of PCSK9 and Urinary Thromboxane Excretion to Cardiovascular Events in Patients With Atrial Fibrillation.
    Pastori D; Nocella C; Farcomeni A; Bartimoccia S; Santulli M; Vasaturo F; Carnevale R; Menichelli D; Violi F; Pignatelli P;
    J Am Coll Cardiol; 2017 Sep; 70(12):1455-1462. PubMed ID: 28911508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of chronic obstructive pulmonary disease on prognosis in atrial fibrillation: A report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry.
    Proietti M; Laroche C; Drozd M; Vijgen J; Cozma DC; Drozdz J; Maggioni AP; Boriani G; Lip GY;
    Am Heart J; 2016 Nov; 181():83-91. PubMed ID: 27823697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study.
    Bonde AN; Lip GY; Kamper AL; Hansen PR; Lamberts M; Hommel K; Hansen ML; Gislason GH; Torp-Pedersen C; Olesen JB
    J Am Coll Cardiol; 2014 Dec; 64(23):2471-82. PubMed ID: 25500231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
    Ikeda Y; Shimada K; Teramoto T; Uchiyama S; Yamazaki T; Oikawa S; Sugawara M; Ando K; Murata M; Yokoyama K; Ishizuka N
    JAMA; 2014 Dec; 312(23):2510-20. PubMed ID: 25401325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.